[Ip-health] Infojustice Roundup – May 9, 2016

Michael Palmedo mpalmedo at wcl.american.edu
Mon May 9 09:53:02 PDT 2016

Infojustice Roundup


Australian Productivity Commission: Pharmaceutical Patent Extensions Cost a Quarter Billion Dollars Annually

[Mike Palmedo] Previous infojustice posts about the Australian Government’s Productivity Commission’s Draft Report on Intellectual Property Arrangements have focused on its recommendation that Australia adopt fair use in its copyright law.  This post highlights the findings regarding the extension of terms for pharmaceutical patents. Australia’s law, in effect since 1999, grants extensions to pharmaceutical firms to make up for time during which the patented drug is awaiting marketing approval. Total patent term may be extended up to a total of 25 years. Click here for more.<http://infojustice.org/archives/36006>

Colombian Civil Society Letter to the Chair of the 2016 CEWG, Describing Imatinib Compulsory License Efforts and Pushback

[Ifarma Foundation, Misión Salud and CIMUN] ... Since November 2014 the undersigned organizations requested the Ministry of Health of Colombia to declare the access to Imatinib (Gleevec(R)) of public interest with compulsory licence purposes. After 15 months of an extended and accidented process, MOH acknowledged that access to imatinib is a matter of public interest, a prerequisite to move to a Compulsory license. Nevertheless there is an enormous pressure from developed countries, from Big Pharma and even from Colombian trade authorities trying to block the Public interest declaration and the Compulsory license. It combines inaccuracies, distortions of international trade rules and even threats of trade claims under the dispute settlement mechanism. We are waiting in the very next hours of days a final decision, but there are reasons to fear the worst. Click here for more.<http://infojustice.org/archives/35984>


EU Pushing Ahead in Support of Open Science

[Tim Vollmer] April saw lots of activity on the open science front in the European Union. On April 19, the European Commission officially announced its plans to create an “Open Science Cloud”. Accompanying this initiative, the Commission stated it will require that scientific data produced by projects under Horizon 2020 (Europe’s €80 billion science funding program) be made openly available by default. Making open data the default will ensure that the scientific community, companies, and the general public can enjoy broad access (and reuse rights) to data generated by European funded scientific projects. Click here for more.<http://infojustice.org/archives/35989>


More information about the Ip-health mailing list